Entering text into the input field will update the search result below

European advisory group backs Novartis biosimilar to J&J's Remicade

Mar. 23, 2018 9:37 AM ETNovartis AG (NVS) StockJNJ, NVSBy: Douglas W. House, SA News Editor4 Comments
  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval for Novartis (NVS +0.1%) unit Sandoz GmbH's Zessly, a biosimilar of Johnson & Johnson's (JNJ -0.1%) Remicade (infliximab).
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG